Pifithrin-β hydrobromide
Based on 21 publication(s) in Google Scholar
Pifithrin-β hydrobromide (PFT β hydrobromide) is a potent p53 inhibitor with an IC50 of 23 μM.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.95%
- CAS. Nr.: 511296-88-1
- Formel: C16H17BrN2S
- Molecular Weight:349.29
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
Glutamine Metabolism Compound Library
HY-L064
-
Neuroprotective Compound Library
HY-L070
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Pifithrin-β hydrobromide
More- Nat Commun. 2025 Feb 25;16(1):1774. [Abstract]
- J Immunother Cancer. 2026 Feb 24;14(2):e013655. [Abstract]
- Cell Commun Signal. 2022 Sep 5;20(1):96. [Abstract]
- Int J Mol Med. 2021 Jul;48(1):122. [Abstract]
- Cancer Cell Int. 2023 Sep 28;23(1):221. [Abstract]
- Front Immunol. 2020 Feb 20;8:75. [Abstract]
- Life Sci. 2021 Sep 1:280:119698. [Abstract]
- Cell Biol Toxicol. 2023 Oct;39(5):2011-2032. [Abstract]
- Int J Mol Sci. 2023 Jul 17;24(14):11554. [Abstract]
- mBio. 2024 Oct 30:e0213724. [Abstract]
- Front Cell Dev Biol. 2020 Jul 29;8:703. [Abstract]
- Sci Rep. 2025 Sep 29;15(1):33534. [Abstract]
- iScience. 2024 Jun 4;27(7):110144. [Abstract]
- Front Mol Biosci. 2021 Aug 19;8:697457. [Abstract]
- FASEB J. 2021 Feb;35(2):e21325. [Abstract]
- J Virol. 2025 Aug 29:e0052925. [Abstract]
- Cell Biol Int. 2025 Jul;49(7):852-864. [Abstract]
- PLoS One. 2018 Sep 20;13(9):e0203833. [Abstract]
- Blood Cells Mol Dis. 2024 Jan:104:102798. [Abstract]
- bioRxiv. 2025 March 21.
- Heliyon. 2024 May 20;10(11):e31431. [Abstract]
Customer Validation & Images
-
WB
Biologische Aktivität
IC50: 23 μM (p53)[1]
Pifithrin-α hydrobromide (PFT β hydrobromide), an inhibitor of the p53 protein, is regarded as a lead compound for cancer and neurodegenerative disease therapy. Pifithrin-α is very unstable in culture medium and rapidly converts to its condensation product pifithrin-β, the N-acetyl derivative[2]. After 24 h, the viability assay shows that the pretreatments with 1 and 10 μM pifithrin-β exerts neuroprotective effects[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 511296-88-1
-
Appearance Solid
-
Molecular Weight 349.29
-
Formel C16H17BrN2S
-
Color White to off-white
-
SMILES
CC1=CC=C(C2=CN3C(SC4=C3CCCC4)=N2)C=C1.Br
-
Synonyms
PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. [Abstract]2025 Feb 25;16(1):1774. PMID: 40000627 -
J Immunother Cancer
Macrophage Mtdh deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production. [Abstract]2026 Feb 24;14(2):e013655. PMID: 41734995 -
Cell Commun Signal
Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. [Abstract]2022 Sep 5;20(1):96. PMID: 36058938 -
Int J Mol Med
Isoquercitrin protects HUVECs against high glucose‑induced apoptosis through regulating p53 proteasomal degradation. [Abstract]2021 Jul;48(1):122. PMID: 33982778 -
Cancer Cell Int
SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3β signaling pathway through P53. [Abstract]2023 Sep 28;23(1):221. PMID: 37770925 -
Front Immunol
MiR-29c-3p Suppresses the Migration, Invasion and Cell Cycle in Esophageal Carcinoma via CCNA2/p53 Axis. [Abstract]2020 Feb 20;8:75. PMID: 32154226 -
Life Sci
Inhibition of miR-431-5p attenuated liver apoptosis through KLF15/p53 signal pathway in S100 induced autoimmune hepatitis mice. [Abstract]2021 Sep 1:280:119698. PMID: 34111466 -
Cell Biol Toxicol
USP8 inhibitor-induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma. [Abstract]2023 Oct;39(5):2011-2032. PMID: 35022897 -
Int J Mol Sci
Calcium/P53/Ninjurin 1 Signaling Mediates Plasma Membrane Rupture of Acinar Cells in Severe Acute Pancreatitis. [Abstract]2023 Jul 17;24(14):11554. PMID: 37511311 -
mBio
2024 Oct 30:e0213724. PMID: 39475231 -
Front Cell Dev Biol
2020 Jul 29;8:703. PMID: 32850823 -
Sci Rep
IL6/STAT3 induced GRWD1 mediates aerobic glycolysis via P53/GLUT1 signal axis in colon carcinoma. [Abstract]2025 Sep 29;15(1):33534. PMID: 41022893 -
iScience
2024 Jun 4;27(7):110144. PMID: 38989466 -
Front Mol Biosci
2021 Aug 19;8:697457. PMID: 34490348 -
FASEB J
2021 Feb;35(2):e21325. PMID: 33508145 -
J Virol
2025 Aug 29:e0052925. PMID: 40879372 -
Cell Biol Int
2025 Jul;49(7):852-864. PMID: 40329699 -
PLoS One
2018 Sep 20;13(9):e0203833. PMID: 30235236
Pifithrin-β hydrobromide purchased from MedChemExpress. Usage Cited in: PLoS One. 2018 Sep 20;13(9):e0203833. [Abstract]
Western Blot analysis of TFDP3, p53 and LC3 in whole cell lysates of MDA-MB-231 transfected and treated with indicated plasmids and reagents. Cells in the treatment group are incubated with 20 μM PFT-beta for 24 hours.
-
Blood Cells Mol Dis
2024 Jan:104:102798. PMID: 37813040 -
-
Heliyon
HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells. [Abstract]2024 May 20;10(11):e31431. PMID: 38845972
Lösungsmittel & Löslichkeit
DMSO : 10 mg/mL (28.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (28.63 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Christodoulou MS, et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem. 2011 Mar 1;19(5):1649-57. [Content Brief]
[2]. Fernández-Cruz ML, et al. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation productpifithrin-β. Life Sci. 2011 Apr 25;88(17-18):774-83. [Content Brief]
[3]. Da Pozzo E, et al. p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells. ACS Chem Neurosci. 2014 May 21;5(5):390-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8630 mL | 14.3148 mL | 28.6295 mL | 71.5738 mL |
| 5 mM | 0.5726 mL | 2.8630 mL | 5.7259 mL | 14.3148 mL | |
| 10 mM | 0.2863 mL | 1.4315 mL | 2.8630 mL | 7.1574 mL | |
| 15 mM | 0.1909 mL | 0.9543 mL | 1.9086 mL | 4.7716 mL | |
| 20 mM | 0.1431 mL | 0.7157 mL | 1.4315 mL | 3.5787 mL | |
| 25 mM | 0.1145 mL | 0.5726 mL | 1.1452 mL | 2.8630 mL |
Pifithrin-β hydrobromide Related Classifications
HY-16702A Related Classifications
Powered by Bioz